Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Michael R. Hayden acquired 5,000 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the completion of the purchase, the director now owns 35,219 shares of the company's stock, valued at approximately $1,275,632.18. This represents a 16.55 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Ionis Pharmaceuticals stock traded down $0.20 during trading hours on Thursday, hitting $36.33. The company had a trading volume of 1,005,815 shares, compared to its average volume of 1,352,247. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $33.33 and a fifty-two week high of $54.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The firm has a market capitalization of $5.74 billion, a P/E ratio of -14.89 and a beta of 0.35. The firm's fifty day moving average is $37.21 and its 200-day moving average is $42.16.
A number of research firms have commented on IONS. William Blair restated an "outperform" rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Guggenheim dropped their target price on Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, October 9th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. StockNews.com downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Finally, Wells Fargo & Company cut their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $60.65.
Get Our Latest Analysis on Ionis Pharmaceuticals
A number of hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Ionis Pharmaceuticals during the second quarter valued at $29,000. GAMMA Investing LLC lifted its holdings in shares of Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after buying an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new position in Ionis Pharmaceuticals in the third quarter worth approximately $40,000. Finally, Prospera Private Wealth LLC bought a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $42,000. 93.86% of the stock is owned by institutional investors and hedge funds.
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.